TickerFacts.

Company research / IOVA

Iovance Biotherapeutics, Inc. (IOVA)

Build a valuation ↗↓ Download CSV

SEC name IOVANCE BIOTHERAPEUTICS, INC. · CIK 0001425205 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Iovance Biotherapeutics, Inc. reported revenue of $263.50M. Revenue grew 60.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $324.97M.

Key ratios (year ended 2025-12-31)

34.3%
Gross margin (computed)
-153.1%
Operating margin
-148.4%
Net margin
-56.0%
Return on year-end equity
60.6%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-05

Headquarters locality: San Carlos · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$324.97M$263.50M$164.07M$1.19Mn/an/an/an/an/an/an/a
Cost of Revenuen/a$173.18M$93.25M$1.03Mn/an/an/an/an/an/an/a
Gross Profit (computed)n/a$90.32M$70.82M$156.0Kn/an/an/an/an/an/an/a
R&D Expensen/a$300.27M$276.23M$333.19M$294.78M$259.04M$201.73M$166.02M$99.83M$71.61M$26.94M
Operating Income-$301.31M-$403.36M-$395.28M-$460.56M-$398.88M-$342.70M-$261.94M-$206.87M-$128.26M-$92.88M-$53.64M
Depreciation & Amortization$36.56M$35.94M$37.60M$21.42Mn/an/an/an/a$956.0K$952.0K$978.0K
EBITDA-$264.75M-$367.42M-$357.68M-$439.14Mn/an/an/an/a-$127.30M-$91.92M-$52.66M
Net Income-$289.52M-$390.98M-$372.18M-$444.04M-$395.89M-$342.25M-$259.58M-$197.56M-$123.58M-$92.06M-$52.89M
EPS (Diluted)n/a-$1.09-$1.28-$1.89-$2.49-$2.23-$1.88-$1.59n/an/an/a
Total Assets$915.53M$913.17M$910.43M$780.35M$663.98M$777.33M$768.46M$344.65M$480.82M$155.37M$171.89M
Total Liabilities$179.49M$214.59M$200.02M$195.74M$164.34M$155.67M$111.96M$45.68M$14.63M$9.89Mn/a
Shareholders' Equity$736.04M$698.58M$710.40M$584.61M$499.64M$621.66M$656.50M$298.97M$466.19M$145.48M$166.92M
Cash & Equivalents$110.77M$163.08M$115.69M$114.89M$231.73M$78.23M$67.33M$13.97M$82.15M$145.37M$106.72M
Operating Cash Flow-$264.18M-$302.41M-$352.98M-$361.82M-$292.76M-$227.94M-$205.13M-$158.89M-$101.25M-$78.71M-$32.67M
Capital Expenditures$32.21M$33.84M$11.07M$22.29M$20.43M$37.57M$46.79M$6.92M$1.20M$1.03M$1.52M
Free Cash Flow-$296.39M-$336.24M-$364.05M-$384.11M-$313.18M-$265.51M-$251.93M-$165.81M-$102.45M-$79.74M-$34.19M
Shares Outstanding452.97M411.94M305.25M256.14M187.81M157.00M147.87M126.41M123.42M73.16M62.25M
EPS (Basic)n/a-$1.09-$1.28-$1.89-$2.49-$2.23-$1.88-$1.59n/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView